Charles Schwab Investment Management Inc. Grows Stock Holdings in Genmab A/S (NASDAQ:GMAB)

Charles Schwab Investment Management Inc. raised its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 134.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 61,177 shares of the company's stock after purchasing an additional 35,073 shares during the quarter. Charles Schwab Investment Management Inc.'s holdings in Genmab A/S were worth $1,277,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC grew its position in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after buying an additional 1,051 shares during the last quarter. Cromwell Holdings LLC boosted its holdings in shares of Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after acquiring an additional 2,496 shares in the last quarter. R Squared Ltd acquired a new position in shares of Genmab A/S during the fourth quarter worth about $93,000. Blue Trust Inc. raised its holdings in Genmab A/S by 33.4% during the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock worth $120,000 after purchasing an additional 1,442 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock valued at $186,000 after purchasing an additional 827 shares during the period. Institutional investors and hedge funds own 7.07% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. Truist Financial cut their price target on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. Finally, Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Genmab A/S presently has a consensus rating of "Moderate Buy" and an average target price of $41.33.

Genmab A/S Trading Up 0.9 %

Shares of GMAB stock traded up $0.16 during trading hours on Wednesday, hitting $18.82. The company's stock had a trading volume of 1,928,595 shares, compared to its average volume of 970,440. Genmab A/S has a twelve month low of $18.48 and a twelve month high of $30.50. The stock has a market cap of $12.45 billion, a price-to-earnings ratio of 10.82, a P/E/G ratio of 2.65 and a beta of 0.98. The business has a fifty day moving average of $20.76 and a 200-day moving average of $21.71.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, equities analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.